home / stock / alxo / alxo news

ALXO News and Press, ALX Oncology Holdings Inc. From 08/10/23

Stock Information
Company Name: ALX Oncology Holdings Inc.
Stock Symbol: ALXO
Market: NASDAQ
Website: alxoncology.com
Menu
ALXO ALXO Quote ALXO Short ALXO News ALXO Articles ALXO Message Board
Get ALXO Alerts

News, Short Squeeze, Breakout and More Instantly...
ALXO - ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update

Advancing Phase 2/3 ASPEN-06 gastric cancer trial with data update expected in Q423 Terminating azacitidine combination development programs: ASPEN-02 in MDS and ASPEN-05 in AML Continuing focus on combinations with anti-cancer antibodies, antibody-drug conjugates, and PD-1/PD-L1 ...
ALXO - GRTS, LX, VRCA and ALXO are among after hour movers

2023-07-21 17:17:13 ET Gainers: Gritstone bio ( GRTS ) +4.8% . LexinFintech Holdings ( LX ) +4.3% . AppLovin ( APP ) +2.9% . Latham Group ( SWIM ) +2.6% . Accuray ( ARAY ) +2.5% . Losers: ALX Oncology Holdings ( ALXO ...

ALXO - BNED, UGRO and NLSP among mid-day movers

2023-07-06 13:08:25 ET Gainers: EdtechX Holdings Acquisition ( EDTX ) +40% . Mullen Automotive ( MULN ) +35% . Genius Sports Limited ( GENI ) +21% . Incannex Healthcare Limited ( IXHL ) +19% . Sweetgreen ( SG ) +18% . urban-g...

ALXO - PTN and MYMD among healthcare movers

2023-07-06 10:07:55 ET Gainers: CytoMed Therapeutics Limited ( GDTC ) +7% . Kronos Bio ( KRON ) +11% . Incannex Healthcare Limited ( IXHL ) +6% . Palatin Technologies ( PTN ) +6% . Losers: VBI Vaccines VBIV -55% . Allarity Th...
ALXO - ALX Oncology gastric cancer candidate wins orphan drug status from EC

2023-06-26 09:38:25 ET The European Commission has awarded orphan drug status to ALX Oncology's ( NASDAQ: ALXO ) evorpacept for gastric cancer. The classification covers both gastric cancer and gastroesophageal junction adenocarcinoma. The US FDA granted orphan drug status...

ALXO - ALX Oncology Receives Orphan Drug Designation from the European Commission for Evorpacept for the Treatment of Patients with Gastric Cancer

SOUTH SAN FRANCISCO, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that evorpacept, a next-generation CD47 b...

ALXO - ALX Oncology GAAP EPS of -$0.74

2023-05-11 17:40:36 ET ALX Oncology press release ( NASDAQ: ALXO ): Q1 GAAP EPS of -$0.74. Cash, cash equivalents and investments as of March 31, 2023 were $256.2 million. ALX Oncology believes its cash, cash equivalents, investments along with the ability to draw down an ...
ALXO - ALX Oncology Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the first quarter end...

ALXO - ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced the initiation of a Phase 2 investigator-s...

ALXO - ALX Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with SARCLISA (isatuximab-irfc) in Patients with Multiple Myeloma

SOUTH SAN FRANCISCO, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced it has entered into a clinical trial col...
Previous 10 Next 10